Skip to main content
Video

Expanded FDA Approval Improves Care Access, Rates of Flu Cases


April 19, 2021

Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at SeqirusGregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means for care access, and how they foresee this new indication improving rates of flu in the future. 

 

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
6 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top